TL;DR: Peptides are short chains of amino acids that can signal cellular activity. There are over a hundred branded peptide compounds in cosmetic chemistry. Three of them have real published human trial data showing skin-level outcomes: matrixyl, copper peptides, and palmitoyl tripeptide-5. The rest are either too new, too small to penetrate, or have data only in cell culture. Most “peptide serums” are marketing on the back of those three.
A reader sent me a peptide serum ingredient list last summer. There were eleven peptides in the formula. The marketing copy claimed each one targeted a different aspect of aging. The bottle was $135 for 30ml.
I sat down with the INCI and looked up each peptide in PubMed. Two had real human trial data. Six had no published data outside in vitro cell culture. Three did not appear in the published literature at all and existed only on supplier datasheets.
This is the state of the peptide market. I am not saying peptides are a scam. I am saying that almost every peptide serum I have seen includes three or four marketing peptides on the back of one or two that actually do something. The skill is knowing which is which.
This is the article I wrote for that reader, and for myself, after a year of trying to work out what peptide actually meant.
What a peptide is
A peptide is a short chain of amino acids, typically two to fifty, linked by peptide bonds. Proteins are long chains of peptides. In skincare, the term peptide refers to short chains, usually three to ten amino acids, that have been designed or selected for a specific biological signalling effect.
The theoretical basis is that certain peptide sequences fit cellular receptors or matrix proteins in ways that trigger a response. Some mimic fragments of collagen breakdown products and signal fibroblasts to make more collagen. Some bind copper and influence wound healing. Some block neurotransmitter release and were marketed as a topical alternative to botulinum toxin.
The mechanisms are plausible. The question for every individual peptide is whether the published trial data shows the effect in actual human skin at the concentrations cosmetics deliver.
For most peptides, the answer is no.
The size problem
I covered this in the brightening article but it applies here too. The general rule from dermatological pharmacology is that molecules above about 500 daltons do not penetrate the stratum corneum in meaningful concentrations. Bos and Meinardi published this in 2000 and it has held up.
Most peptides are above 500 daltons. A pentapeptide (five amino acids) ranges from about 500 to 800 daltons depending on the amino acids involved. A heptapeptide is usually above 800.
This is why cosmetic peptides are usually conjugated to lipid carriers. Palmitoyl. Myristoyl. The fatty acid chain provides lipid solubility that allows the peptide to cross the corneum. The Lintner and Peschard 2000 paper in International Journal of Cosmetic Science is the foundational work on this approach.
The lipid conjugation works. It also means the peptide is no longer the simple signalling molecule it was designed to mimic. It is a modified, larger molecule that has to release the active fragment in the skin. The efficiency of that release in vivo is not always well-characterised.
This is why so many peptide products show in vitro effects that do not translate to in vivo outcomes. The cell culture studies use the unconjugated peptide directly on the cell. The skin product uses the conjugated form that has to cross the corneum and release the active. The first one works in the lab. The second one is what is in the bottle.
The three with real data
Of the peptides currently in the cosmetic market, three have published human trial data that I find convincing.
Matrixyl (palmitoyl pentapeptide-4, also called pal-KTTKS)
This is the most studied cosmetic peptide. The Robinson 2005 trial in International Journal of Cosmetic Science compared palmitoyl pentapeptide-4 at 3 ppm to placebo over twelve weeks on 93 women. The peptide arm showed measurable improvement in wrinkle depth and skin thickness on profilometry and ultrasound.
This is one trial. It is industry-funded (Procter and Gamble at the time). The effect size is modest. But it is real human skin, real measurement, and a placebo control. That puts it ahead of 95 percent of peptide actives.
Matrixyl is now in many formulations. The original Procter and Gamble work used 3 ppm, which is 0.0003 percent. Most cosmetic formulations use higher concentrations, sometimes up to 0.1 percent, though dose-response data above 3 ppm is limited.
The reasonable interpretation: matrixyl is a real active with modest published effect. It is not transformative. It is not nothing.
Copper peptides (GHK-Cu, glycyl-histidyl-lysine bound to copper)
GHK is a tripeptide naturally present in human plasma and saliva. It declines with age. When bound to copper as GHK-Cu, it has demonstrated wound-healing effects in animal models and limited human data on skin remodelling.
The data is older. Pickart and Margolina published the major reviews in the 1990s and 2000s. The Schagen 2017 cosmetics review consolidates the human trial data, which is thinner than Matrixyl’s but exists.
GHK-Cu has the advantage of being a small molecule (340 daltons) that can penetrate without lipid conjugation. The disadvantages are formulation difficulties (copper is reactive with vitamin C, hydroxy acids, and some preservatives) and unpredictable colour (the formulation is blue, which limits packaging options).
The Niod Copper Amino Isolate Serum and the Skin Biology line are the most commonly available formulations. I have used Niod for six months periodically. The data convinces me it does something. The magnitude I am not sure about.
Palmitoyl tripeptide-5 (Syn-Coll)
Tripeptide-5 was designed to mimic a fragment of thrombospondin that activates TGF-beta and stimulates collagen synthesis. The published trials are smaller than Matrixyl but include some in vivo human data showing improvement in skin elasticity and wrinkle measurements over 12 to 24 weeks.
The trials are funded by the manufacturer (Pentapharm, now DSM). The data is reasonable but the independence is limited. I include it on the list because it is one of the few peptides where the mechanism, the delivery, and the human data all line up at least somewhat.
Argireline and the botox question
Argireline (acetyl hexapeptide-8) deserves its own paragraph because it is the most marketed and most overclaimed peptide in cosmetics. It is sold as a topical Botox alternative because it inhibits the SNARE complex that drives neurotransmitter release.
The mechanism is real in vitro. The human trial data is poor. The original Lintner studies showed some reduction in wrinkle depth in small cohorts. Independent replication has been limited and the magnitude of effect in published trials is small.
The bigger problem is that Argireline is a hexapeptide of about 900 daltons. It does not cross the stratum corneum efficiently without a substantial delivery system, and even when conjugated, the question of how much reaches the muscle to inhibit synapse activity is not convincingly answered in any study I have read.
I would not buy Argireline as a botulinum alternative. The marketing has gotten ahead of the data.
The others
There are over a hundred branded peptides in the cosmetic supply chain. Matrixyl 3000, Matrixyl Synthe-6, Snap-8, Leuphasyl, Eyeseryl, SYN-AKE, Decorinyl, Boswelox, Lipotec’s various sequences. Most of these are sold to formulators on the basis of in vitro data and supplier marketing materials. Few have independent human trial data.
This is not a moral judgement. New active development relies on early-stage data. The problem is the gap between supplier-level data and consumer-level marketing. The supplier says “in vitro evidence of fibroblast stimulation.” The brand says “boosts collagen by 71 percent.” Both can be technically defensible. They mean different things.
When you see a peptide serum claim a specific percentage improvement, ask which study the number comes from. If the answer is a supplier datasheet rather than a peer-reviewed publication, treat the claim as marketing.
Where I have been wrong about peptides
I used to assume that any product with peptides was probably doing something. Peptides sound scientific. The mechanism is elegant. The published research exists somewhere.
I was wrong. The published research is often a single small in vitro paper from the supplier and a single industry-funded clinical trial with measurement choices that favour the active. The independent replication that you would need to be confident is rare. The peptide market is closer to the supplement market in its evidence base than to the prescription drug market.
The two peptides I still buy are matrixyl-based formulations (when bundled with other actives I want, not for the peptide alone) and the Niod copper peptide product (when I am specifically working on barrier and texture). I am not convinced enough to spend $100 on a serum that is mostly peptides.
What I do now
I treat peptides as a supporting active, not a primary one. If a moisturiser includes matrixyl or copper peptides at reasonable concentrations and is otherwise well-formulated, I am happy to use it. I do not spend extra for products marketed primarily on peptides.
My primary anti-aging actives are tretinoin or adapalene, sunscreen, and azelaic acid. These have decades of data. The peptides are at best a small additional contribution.
The Inkey List Peptide Moisturiser and the Olay Regenerist line are reasonable peptide-containing products at sensible prices. The luxury peptide serums above $100 are mostly paying for branding and packaging.
The contrarian section: where peptides might surprise us
The peptide story is still being written. The original Matrixyl work is twenty years old. Newer peptides like the GLP-1 agonists in oral medicine show that the peptide field can produce real clinical effects when the mechanism is genuine and the delivery works.
It is possible that some of the peptides currently being marketed with limited data will turn out to have real effects when properly studied. It is also possible that most will not. The honest position is that we do not know yet for most of them.
I would not bet against peptides as a category. I would bet against any individual peptide claim that exceeds the published data, which is most of what the market sells.
Frequently asked
Are peptides safer than retinoids? Generally yes, in that the irritation profile is low and they do not cause peeling. They are also generally less effective at the visible outcome level.
Can I layer peptides with vitamin C? Most cosmetic peptides tolerate vitamin C in the same routine. Copper peptides do not. The copper binds to ascorbate and oxidises. Use them on different days.
Should I use a peptide serum if I already use retinol? Maybe. The combination has reasonable theoretical justification (retinoid drives turnover, peptides signal new matrix). The independent evidence that the combination outperforms either alone is limited.
What about plant-based peptide alternatives? Plant peptides are real but the cosmetic versions are usually short oligopeptides with limited published research. Treat them like the cosmetic peptides, not as a separate category.
Closing
The reader who emailed me with the eleven-peptide serum has since switched to a much cheaper product with matrixyl as the main peptide. Her skin is similar. Her bank account is happier.
Peptide skincare is not a scam. It is an active category with three to five molecules that have decent published evidence and a long tail of compounds that are mostly supplier marketing. The skill is filtering.
If you want results, the active that has the strongest evidence in your category (tretinoin or adapalene for cellular turnover, azelaic acid for pigment, sunscreen for protection) will outperform a peptide stack at half the price. Peptides are an addition, not a foundation.
Linked tools to work out where peptides might fit: the build-from-scratch plan, the niacinamide vs vitamin C decision tree, and the layering order.
References
- Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science, 2000. PMID: 18503411.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017. DOI: 10.3390/cosmetics4020016.
- Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. Journal of Cosmetic Dermatology, 2009. PMID: 19735514.
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science, 2005. PMID: 18492178.
Related Elelaf tools
Sources
- Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science, 2000. PMID: 18503411.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017. DOI: 10.3390/cosmetics4020016.
- Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. Journal of Cosmetic Dermatology, 2009. PMID: 19735514.
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science, 2005. PMID: 18492178.